The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets

Journal of Pain

Volumn 13, Issue 1, 2012, Pages 90-99

  Fiske, William D ^a   Jobes, Janet ^a   Xiang, Qinfang ^a   Chang, Sou Chan ^a   Benedek, Irma H ^a  

^a ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Bioavailability; dissolution; ethanol; opioid; oxymorphone; pharmacokinetics

Indexed keywords

ALCOHOL; NALTREXONE; OXYMORPHONE;

ADULT; AQUEOUS SOLUTION; ARTICLE; CROSSOVER PROCEDURE; CRUSH RESISTANT EXTENDED RELEASE TABLET; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG RELEASE; EXTENDED RELEASE TABLET; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TABLET FORMULATION; VOMITING;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; OXYMORPHONE; TIME FACTORS; YOUNG ADULT;

EID: 84855258471     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2011.10.011     Document Type: Article

References (32)

1. M.P. Adams, and H. Ahdieh Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study Pharmacotherapy 24 2004 468 476 (Pubitemid 38420533)
2. E.J. Cone, and Y.H. Caplan Urine toxicology testing in chronic pain management Postgrad Med 121 2009 91 102
3. de Kater A, Butera P, Haux E, Schoenhard G, Friedmann N: The effects of alcohol on an abuse-resistant formulation of controlled-release oxycodone. Presented at the International Association for the Study of Pain. Glasgow, UK, August 17-22, 2008
4. ® (hydromorphone hydrochloride). Full Prescribing Information, Abbott Laboratories, North Chicago, IL, 2008
5. ® (fentanyl transdermal system). Full Prescribing Information, Janssen Pharmaceuticals, Inc., Titusville, NJ, 2008
6. Fiske WD, Benedek IH, Ahdieh H: Bioavailability of oxymorphone extended-release following consumption of alcohol or food. Presented at 27th Annual Scientific Meeting of the American Pain Society, Tampa, Florida, May 8-10, 2008
7. Fiske WD, Benedek IH, Ahdieh H: Pharmacokinetics of oxymorphone extended-release tablets following consumption of food or alcohol. Presented at the American College of Clinical Pharmacy 2008 Annual Meeting. Louisville, KY, October 19-22, 2008
8. Fiske WD, Photivihok G, Benedek IH: The effects of graded concentrations of oral ethanol on the in-vivo bioavailability of oxymorphone extended release tablets. Presented at the American Academy of Pain Medicine Annual Meeting. Orlando, FL, February 12-16, 2008
9. Fiske WD, Photivihok G, Benedek IH: The effects of graded concentrations of oral ethanol on the in-vivo bioavailability of oxymorphone HCl extended release (ER) tablets. Presented at the American Society for Clinical Pharmacology and Therapeutics 10th Annual Meeting, Anaheim, CA, March 21-24, 2007
10. A. Franke, I.A. Nakchbandi, A. Schneider, H. Harder, and M.V. Singer The effect of ethanol and alcoholic beverages on gastric emptying of solid meals in humans Alcohol Alcohol 40 2005 187 193 (Pubitemid 40613831)
11. N.Y. Gabrail, C. Dvergsten, and H. Ahdieh Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study Curr Med Res Opin 20 2004 911 918 (Pubitemid 38821530)
12. L.M. Garnier, A.M. Arria, K.M. Caldeira, K.B. Vincent, K.E. O'Grady, and E.D. Wish Nonmedical prescription analgesic use and concurrent alcohol consumption among college students Am J Drug Alcohol Abuse 35 2009 334 338
13. M.E. Hale, H. Ahdieh, T. Ma, and R. Rauck Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study J Pain 8 2007 175 184 (Pubitemid 46186162)
14. F. Johnson, G. Wagner, S. Sun, and J. Stauffer Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules J Pain 9 2008 330 336
15. F.K. Johnson, S. Ciric, S. Boudriau, J. Kisicki, and J. Stauffer Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules J Clin Pharmacol 2011 May 18 [Epub ahead of print]
16. ® (morphine sulfate sustained release capsules). Full Prescribing Information, Alpharma, Piscataway, NJ, 2007
17. E. Kalso, J.E. Edwards, R.A. Moore, and H.J. McQuay Opioids in chronic non-cancer pain: Systematic review of efficacy and safety Pain 112 2004 372 380 (Pubitemid 39550738)
18. N. Katz Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep 10 2008 11 18
19. N. Katz, R. Rauck, H. Ahdieh, T. Ma, R. Gerritsen van der Hoop, R. Kerwin, and G. Podolsky A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain Curr Med Res Opin 23 2007 117 128 (Pubitemid 46191677)
20. S.E. McCabe, J.A. Cranford, M. Morales, and A. Young Simultaneous and concurrent polydrug use of alcohol and prescription drugs: Prevalence, correlates, and consequences J Stud Alcohol 67 2006 529 537 (Pubitemid 43856728)
21. ® ER (oxymorphone hydrochloride extended-release tablets). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, 2008
22. ® (oxycodone HCl controlled-release tablets). Full Prescribing Information, Purdue Pharma LLP, Stamford, CT, 2007
23. S.D. Passik, L. Hays, N. Eisner, and K.L. Kirsh Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation J Pain Palliat Care Pharmacother 20 2006 5 13 (Pubitemid 43962738)
24. X. Ruan, T. Chen, J. Gudin, J.P. Couch, and S. Chiravuri Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature J Opioid Manag 6 2010 300 303
25. G. Sathyan, K. Sivakumar, and J. Thipphawong Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol Curr Med Res Opin 24 2008 297 305 (Pubitemid 351160261)
26. G. Stacher, H. Bergmann, G. Gaupmann, C. Schneider, A. Kugi, J. Hobart, A. Binder, and G. Mittelbach-Steiner Fat preload delays gastric emptying: Reversal by cisapride Br J Clin Pharmacol 30 1990 839 845
27. D.C. Turk, and M.J. Cohen Sleep as a marker in the effective management of chronic osteoarthritis pain with opioid analgesics Semin Arthritis Rheum 39 2010 477 490
28. ® (tramadol hydrochloride). Full Prescribing Information, Ortho-McNeil, Raritan, NJ, 2008
29. US Food and Drug Administration: Alert for healthcare professionals: hydromorphone hydrochloride extended-release capsules (marketed as Palladone). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm129288.htm Accessed November 9, 2010
30. US Food and Drug Administration Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products/general considerations 2003 US Food and Drug Administration, Center for Drug Evaluation and Research Rockville, MD
31. T.W. Victor, N. Alvarez, and E. Gould Opioid prescribing practices in chronic pain management: Guidelines do not sufficiently influence clinical practice J Pain 10 2009 1051 1057
32. M. Walden, F.A. Nicholls, K.J. Smith, and G.T. Tucker The effect of ethanol on the release of opioids from oral prolonged-release preparations Drug Dev Ind Pharm 33 2007 1101 1111 (Pubitemid 350034834)